Steminent Biotherapeutics Inc. (TPEX:7729)
Taiwan
· Delayed Price · Currency is TWD 80.20
-1.10 (-1.35%)
At close: Mar 9, 2026
Steminent Biotherapeutics Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
n/a
Market Cap
5.34B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 941.00K | 305.00K | 47.96% |
| Dec 31, 2022 | 636.00K | -1.49M | -70.01% |
| Dec 31, 2021 | 2.12M | -49.35M | -95.88% |
| Dec 31, 2020 | 51.47M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Locus Cell | 5.18M |
| AnnJi Pharmaceutical | 23.85M |
| Pharmosa Biopharm | 136.72M |
| CHO Pharma | 3.21M |
| Panion & Bf Biotech | 2.04B |
| UnicoCell Biomed | 30.10M |
| Sinphar Pharmaceutical | 3.35B |
| OBI Pharma | 49.29M |